CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Δ12, 14-PGJ2- and indomethacin-induced agonist responses

Hiromi Sugimoto, Michitaka Shichijo, Mitsuhiro Okano, Kevin B. Bacon

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)


We previously showed that ramatroban (Baynas™), a thromboxane A 2 (TxA2) antagonist, had inhibited prostaglandin D 2 (PGD2)-stimulated human eosinophil migration mediated through activation of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). However, detailed pharmacological characterization of its inhibitory activity has not been described. In the present study, we showed that [3H]ramatroban bound to a single receptor site on CRTH2 transfectants with a similar Kd value (7.2 nM) to a TxA2 receptor (8.7 nM). We also demonstrated that ramatroban inhibited PGD 2-, 15-deoxy-Δ12, 14-PGJ2 (15d-PGJ 2)- and indomethacin-induced calcium responses on CRTH2 transfectants in a competitive manner with similar pA2 values (8.5, 8.5, and 8.6, respectively). This is the first report showing the evidence for direct binding of ramatroban to CRTH2, revealing its competitive inhibitory effects and another interesting finding that PGD2, indomethacin and 15d-PGJ2 share the same binding site with ramatroban on CRTH2.

Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalEuropean Journal of Pharmacology
Issue number1-3
Publication statusPublished - Nov 7 2005


  • 15d-PGJ (15-deoxy-Δ -PGJ)
  • CRTH2 (Chemoattractant receptor-homologous molecule expressed on Th2 cells)
  • Competitive inhibitory effect
  • Indomethacin
  • Ramatroban

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'CRTH2-specific binding characteristics of [<sup>3</sup>H]ramatroban and its effects on PGD<sub>2</sub>-, 15-deoxy-Δ<sup>12, 14</sup>-PGJ<sub>2</sub>- and indomethacin-induced agonist responses'. Together they form a unique fingerprint.

Cite this